Cardiogenic shock: diagnosis, phenotyping and management.

Area of Science:

• Cardiology
• Critical Care Medicine
• Precision Medicine

Background:

• Cardiogenic shock (CS) is a life-threatening condition characterized by severe end-organ hypoperfusion due to cardiac failure.
• High mortality rates underscore the urgent need for improved therapeutic strategies in CS.
• Current treatment paradigms are evolving with advancements in technology and personalized medicine approaches.

Purpose of the Study:

• To explore the potential of precision medicine in tailoring interventions for cardiogenic shock.
• To highlight the importance of integrating diverse patient data (genetic, biomarker, imaging, clinical) for personalized CS management.
• To emphasize the critical need for evidence-based integration of novel therapies into clinical practice.

Main Methods:

• Review of emerging technologies in hemodynamic monitoring and mechanical circulatory support.
• Analysis of advancements in targeted pharmacologic therapies for CS.
• Discussion on the role of data integration from clinical trials, registries, and meta-analyses.

Main Results:

• Precision medicine holds promise for individualized CS treatment strategies.
• Novel hemodynamic monitoring, advanced mechanical support, and targeted drugs expand therapeutic options.
• Integrating these innovations requires careful validation through robust clinical evidence.

Conclusions:

• A shift towards a patient-centered, nuanced approach in CS management is advocated.
• Balancing innovation with scientific rigor, particularly randomized-controlled trials, is paramount for patient safety and efficacy.
• Collaborative efforts and data sharing are crucial to advance evidence-based precision medicine in cardiogenic shock.